Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Follow-Up Questions
Jupiter Neurosciences Inc의 CEO는 누구입니까?
Mr. Christer Rosen은 2016부터 회사에 합류한 Jupiter Neurosciences Inc의 Chairman of the Board입니다.
JUNS 주식의 가격 성능은 어떻습니까?
JUNS의 현재 가격은 $1.45이며, 전 거래일에 increased 1.74% 하였습니다.
Jupiter Neurosciences Inc의 주요 사업 주제나 업종은 무엇입니까?
Jupiter Neurosciences Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Jupiter Neurosciences Inc의 시가총액은 얼마입니까?
Jupiter Neurosciences Inc의 현재 시가총액은 $50.6M입니다
Jupiter Neurosciences Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Jupiter Neurosciences Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
